Arizona Center for Cancer Care

Announced: 01/30/2017 | Value: Undisclosed

Exclusive financial advisor to AZCCC in connection with its Joint Venture with HonorHealth

CoLucid Pharmaceuticals

Announced: 01/18/2017 | Value: $960 million

Exclusive sell-side advisor to CoLucid Pharmaceuticals on its sale to Eli Lilly and Company

Ipsen

Announced: 01/08/2017 | Value: $575 million plus up to $450 million in contingent payments

Exclusive financial advisor to Ipsen on its acquisition of Onivyde from Merrimack Pharmaceuticals

OncoGenex Pharmaceuticals

Announced: 01/05/2017 | Value: Undisclosed

Exclusive financial advisor to OncoGenex Pharmaceuticals on its all-stock merger agreement with Achieve Life Science

Shire plc (NASDAQ:SHPG)

Announced: 01/04/2017 | Value: Undisclosed

Exclusive financial advisor to Shire on the spin-out of its MRT platform to RaNA Therapeutics

Universal American

Announced: 11/17/2016 | Value: $800 million

MTS advised Universal American on its sale to WellCare Health Plans

Ocular Technologies (an Auven Therapeutics portfolio company)

Announced: 10/26/2016 | Value: $40 million plus contingent payments

Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease

Horizon Pharma Plc

Announced: 09/12/2016 | Value: $800 million

Lead financial advisor to Horizon Pharma Plc on its acquisition of Raptor Pharmaceutical

PathGroup

Announced: 08/01/2016 | Value: Undisclosed

Exclusive financial advisor to PathGroup in connection with its sale to Pritzker Group Private Capital

Dana-Farber Cancer Institute

Announced: 07/29/2016 | Value: $168 million

Long-term exclusive financial advisor to DFCI in the structured sale of a portion of its royalty interests in certain PD-L1 products and product candidates

Medical Research Council Technology

Announced: 07/08/2016 | Value: $150 million

Exclusive financial advisor to MRCT in the structured sale of a portion of its worldwide royalty interests in KEYTRUDA

Bloom Health

Announced: 07/06/2016 | Value: Undisclosed

Sole advisor to Bloom Health on its sale to Empyrean Benefit Solutions

Verona Pharma

Announced: 06/17/2016 | Value: $63.3 million

Sole US placement agent for Verona Pharma in connection with raising $63.3 million in a PIPE financing

Celator Pharmaceuticals

Announced: 05/31/2016 | Value: $1.5 billion

Exclusive financial advisor to Celator in connection with its sale to Jazz Pharmaceuticals

Synta Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Financial Advisor to Synta Pharmaceuticals on its all-stock merger agreement with Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Announced: 04/14/2016 | Value: Undisclosed

Strategic Advisor to Madrigal Pharmaceuticals on its all-stock merger agreement with Synta Pharmaceuticals

Starmount

Announced: 04/04/2016 | Value: $127 million

Exclusive financial advisor to Starmount in connection with its sale to Unum Group (NYSE: UNM)

Celator Pharmaceuticals

Announced: 03/23/2016 | Value: $44 million

Financial advisor to Celator Pharmaceuticals (NASDAQ:CPXX) on its $43.7 Million Public Offering

Caladrius Biosciences

Announced: 03/14/2016 | Value: $25 million

Exclusive financial advisor to Caladrius Biosciences on its Strategic Global Collaboration and Asia License Agreement with Hitachi Chemical (19.9% Equity Stake for $19.4 Million and $5.6 Million Upfront)

Signature Hospice and Home Health

Announced: 03/09/2016 | Value: $84 million

Exclusive financial advisor to Genesis Healthcare (NYSE: GEN) on the sale of its Signature Hospice and Home Health operations to Hospice Compassus

Laurel Health Care Company

Announced: 02/02/2016 | Value: Undisclosed

Sale of real estate assets to Omega Healthcare Investors as well as the sale of operations to Ciena Healthcare

Tarveda Therapeutics (formerly Blend Therapeutics)

Announced: 01/27/2016 | Value: $38 million

Sole placement agent for Tarveda Therapeutics on its $38 Million Private Placement

Acorda Therapeutics

Announced: 01/19/2016 | Value: $363 million

Financial advisor to Acorda Therapeutics on the acquisition of Biotie Therapies

Aprecia Pharmaceuticals

Announced: 01/14/2016 | Value: $50 million

Sole placement agent for Aprecia Pharmaceuticals on its $50 Million Private Placement

Zymeworks

Announced: 01/08/2016 | Value: $62 million

Lead placement agent for Zymeworks in connection with raising $61.5 million of Series A financing

Diffusion Pharmaceuticals LLC

Announced: 12/15/2015 | Value: Undisclosed

Exclusive financial advisor to Diffusion Pharmaceuticals on its merger with RestorGenex Corporation

Velicept Therapeutics

Announced: 11/24/2015 | Value: $20 million

Sole placement agent for Velicept Therapeutics on its $20 million Private Placement

Examination Management Services Inc.

Announced: 11/03/2015 | Value: Undisclosed

Exclusive financial advisor to EMSI in connection with its sale to Beecken Petty O’Keefe

StrataDx

Announced: 10/01/2015 | Value: Undisclosed

Exclusive financial advisor to StrataDx in connection with its sale to Dermatopathology Experts

Health Diagnostic Laboratory

Announced: 09/11/2015 | Value: $37.1 million

Financial advisor to HDL in its Section 363 sale to True Health Diagnostics

Tripex Pharmaceuticals

Announced: 08/20/2015 | Value: $418.4 million

Exclusive advisor for Tripex in connection with its sale of Quinsair to Raptor Pharmaceuticals

Celsus Therapeutics

Announced: 08/18/2015 | Value: $75 million

Placement agent for Celsus in connection with raising $75 million in a PIPE financing

TeamHealth

Announced: 08/04/2015 | Value: $1.6 billion

Financial advisor to TeamHealth on its acquisition of IPC Healthcare

Celsus Therapeutics

Announced: 07/13/2015 | Value: Undisclosed

Financial advisor to Celsus Therapeutics on its merger with Volution Immuno Pharmaceuticals

ARCA biopharma

Announced: 06/11/2015 | Value: $37 million

Sole placement agent for ARCA biopharma in connection with raising $37 million in a PIPE financing

University of Maryland Medical System

Announced: 05/14/2015 | Value: Not Disclosed

Exclusive advisor for the University of Maryland Medical System in connection with its acquisition of Riverside Health

Baxter International Inc.

Announced: 05/12/2015 | Value: $900 million

Financial advisor to Baxter International Inc. on its acquisition of Oncaspar Portfolio from Sigma-Tau Finanziaria S.p.A

ImmunoGen, Inc.

Announced: 03/30/2015 | Value: $200 million

Financial advisor to ImmunoGen, Inc. in the structured sale of a portion of its worldwide royalty interests in Kadcyla

Champions Oncology

Announced: 03/12/2015 | Value: $14 million

Sole placement agent for Champions Oncology in connection with raising $14 million in a PIPE financing

TRACON Pharmaceuticals, Inc.

Announced: 01/29/2015 | Value: $41 million

Financial advisor to TRACON Pharmaceuticals, Inc. in connection with its Initial Public Offering

Regado Biosciences

Announced: 01/14/2015 | Value: Not Disclosed

Financial advisor to Regado Biosciences on its merger with Tobira Therapeutics

Otsuka Pharmaceutical

Announced: 12/02/2014 | Value: $3.54 billion

Financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Avanir Pharmaceuticals, Inc.

Community Health Systems

Announced: 11/07/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Riverview Regional Medical Center to Prime Healthcare Services

GE Capital, Healthcare Financial Services

Announced: 11/05/2014 | Value: $305 million

Exclusive financial advisor to GE Capital, Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Aviv REIT

Paul Capital

Announced: 10/17/2014 | Value: Not Disclosed

Exclusive financial advisor to Paul Capital on the secondary sale of royalty streams generated by seven pharmaceuticals

Community Health Systems

Announced: 10/13/2014 | Value: Not Disclosed

Exclusive financial advisor to Community Health Systems on its divestiture of Carolina Pines Regional Medical Center to Capella Healthcare

WellSpring Pharmaceutical

Announced: 10/03/2014 | Value: Not Disclosed

Exclusive financial advisor to WellSpring Pharmaceutical Corporation on the sale of its Prescription Pharmaceutical Business

Acorda Therapeutics

Announced: 09/24/2014 | Value: $525 million

Financial advisor to Acorda Therapeutics on the acquisition of Civitas Therapeutics

TRACON Pharmaceuticals

Announced: 09/22/2014 | Value: $27 million

Lead placement agent for Tracon in connection with raising $27.0 million of Series B financing

Aerie Pharmaceuticals, Inc.

Announced: 09/09/2014 | Value: $125 million

Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities

Skilled Healthcare Group

Announced: 08/18/2014 | Value: NA

Exclusive financial advisor to Skilled Healthcare Group Inc. (NYSE:SKH) on its merger with Genesis HealthCare

AesRx

Announced: 07/09/2014 | Value: Not Disclosed

Exclusive financial advisor to AesRx, LLC on its sale to Baxter International Inc.

Nicox

Announced: 07/02/2014 | Value: Up to $120 million

Exclusive financial advisor to Nicox, SA on its acquisition of Aciex Therapeutics, Inc.

Vistria

Announced: 06/24/2014 | Value: Not Disclosed

Financial advisor to Vistria on its acquisition of Angel MedFlight

Cymetrix

Announced: 05/14/2014 | Value: Up to $100 million

Financial advisor to Cymetrix on its sale to Navigant

Alder Biopharmaceuticals Inc

Announced: 05/08/2014 | Value: $80 million

Financial advisor to Alder Biopharmaceuticals Inc in connection with its Initial Public Offering

Corrona

Announced: 04/17/2014 | Value: Not Disclosed

MTS acted as financial advisor on the growth recapitalization of Corrona

Kaléo

Announced: 04/07/2014 | Value: $150 million

Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products

Promise Healthcare

Announced: 04/02/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its acquisition of six healthcare facilities including four long-term acute care hospitals and two skilled nursing facilities

Oxygen Biotherapeutics

Announced: 03/18/2014 | Value: $59.8 million

MTS served as underwriter for the transaction and led efforts with institutional investors participating in the offering

Promise Healthcare

Announced: 03/17/2014 | Value: Not Disclosed

Financial advisor to Promise Healthcare, Inc. on its restructuring

NuPathe Inc.

Announced: 01/21/2014 | Value: $268 million

Financial advisor to NuPathe Inc. on its sale to Teva Pharmaceutical Industries.

Iroko Pharmaceuticals

Announced: 11/21/2013 | Value: $75 million

Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac)

Almost Family, Inc.

Announced: 11/5/2013 | Value: $75.5 million

Financial advisor to Almost Family, Inc. on its acquisition of SunCrest Healthcare

Miraca Life Sciences

Announced: 10/23/2013 | Value: Not Disclosed

Financial advisor to Miraca Life Sciences on its acquisition of PLUS Diagnostics

La Jolla Pharmaceutical

Announced: 09/25/2013 | Value: $10 million

Sole placement agent for La Jolla Pharmaceutical Company in connection with raising $10.0 million through common and preferred shares

Celsus Therapeutics

Announced: 09/19/2013 | Value: $12.5 million

Placement agent for Celsus Therapeutics in connection with raising $12.5 million through common shares

QuantiaMD

Announced: 9/3/2013 | Value: $10 million

Sole placement agent for Quantia Communications, Inc. on its $10 million Private Placement

Acorda Therapeutics

Announced: 7/9/2013 | Value: Not Disclosed

Financial advisor to Acorda Therapeutics on the acquisition of Qutenza™ and NP-1998 from NeurogesX

University of Pennsylvania

Announced: 6/25/2013 | Value: $55 million

Financial advisor to University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid

Laboratory Partners

Announced: 6/3/2013 | Value: Not Disclosed

Financial advisor to Laboratory Partners on the sale of its physician outreach business

AmeriHealth Caritas

Announced: 5/1/2013 | Value: Not Disclosed

Financial advisor to AmeriHealth Caritas on its acquisition of DC Chartered Health Plan assets

RXi Pharmaceuticals Corporation

Announced: 3/1/2013 | Value: $16.4 million

Sole placement agent for RXI Pharmaceuticals Corp. in connection with raising $16.4 million through the sale of common shares

Progenics Pharmaceuticals

Announced: 1/22/2013 | Value: Up to $105 million

Financial advisor to Progenics Pharmaceuticals, Inc on its acquisition of Molecular Insight Pharmaceuticals

TractManager Inc.

Announced: 1/7/2013 | Value: Not Disclosed

Exclusive financial advisor to TractManager, Inc. in connection with the majority recapitization investment by Arsenal Capital Partners

Florida Clinical Laboratory

Announced: 12/31/2012 | Value: Not Disclosed

Exclusive financial advisor to Florida Clinical Laboratory on its sale to Bio-Reference Laboratories, Inc.

BioScrip

Announced: 12/13/2012 | Value: $70 million

Financial advisor to BioScrip Inc. on its acquisition of HomeChoice Partners, Inc. from DaVita HealthCare Partners

GE Capital, Healthcare Financial Services

Announced: 12/1/2012 | Value: Not Disclosed

Exclusive financial advisor to GE Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Formation Capital

MethylGene

Announced: 11/21/2012 | Value: $26 million

Acted as a placement agent for MethylGene in connection with raising $26MM in a PIPE financing

NuPathe

Announced: 10/23/2012 | Value: $28 million

Co-placement agent for NuPathe, Inc. in connection with raising $28 million in a PIPE financing

Fibrocell Science

Announced: 10/8/2012 | Value: $45 million

Lead placement agent for Fibrocell Science, Inc. in connection with raising $45 million in a PIPE financing. Strategic Advisor to Fibrocell Science, Inc on its strategic collaboration with Intrexon

Jazz Pharmaceuticals

Announced: 9/6/2012 | Value: $95 Million

Exclusive financial advisor to Jazz Pharmaceuticals on the sale of its Women’s Health Business to Meda AB

Idenix Pharmaceuticals

Announced: 8/2/2012 | Value: $176 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $176 million follow-on public offering of common stock

BioScrip

Announced: 7/31/2012 | Value: $41 million

Financial advisor to BioScrip Inc. on its acquisition of InfuScience from Cressey & Company

Not Disclosed

Announced: 6/30/2012 | Value: Not Disclosed

Financial advisor to Undisclosed Public Buyer on its acquisition of Healthy Circles

Sun Healthcare

Announced: 6/20/2012 | Value: $275 million

Exclusive financial advisor to Sun Healthcare on its sale to Genesis Healthcare

Lumeris Corporation

Announced: 2/14/2012 | Value: Not Disclosed

Financial advisor to Lumeris Corp. on its acqusition of NaviNet in partnership with Highmark, Horizon Blue Cross Blue Shield of New Jersey and Independence Blue Cross

BioScrip

Announced: 2/2/2012 | Value: $285 million

Financial advisor to BioScrip Inc. on its sale of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens

Idenix Pharmaceuticals

Announced: 11/16/2011 | Value: $61.1 million

Financial advisor to Idenix Pharmaceuticals, Inc. on its $61 million follow-on public offering of common stock

A.P. Pharma

Announced: 6/29/2011 | Value: $24 million

Sole placement agent for AP Pharma in connection with raising $24 million in a PIPE financing

Highmark

Announced: 6/28/2011 | Value: $1.3 billion

Financial advisor to Highmark Inc. in connection with its acquisition of West Penn Allegheny Health System

Trimeris

Announced: 6/13/2011 | Value: $285 million

Exclusive financial advisor to Trimeris Inc. on its reverse merger with Synageva BioPharma Corp

Advanced Vision Research

Announced: 5/3/2011 | Value: $26 million

Exclusive financial advisor to Advanced Vision Research on its sale to Akorn, Inc.

MethylGene

Announced: 3/24/2011 | Value: $35 million

Sole placement agent for MethylGene in connection with raising $35 million in a PIPE financing

Intercell AG

Announced: 2/23/2011 | Value: $45.5 million

Financial advisor to Intercell AG related to the issuance of senior unsecured convertible notes

Sol Amor Hospice

Announced: 1/3/2011 | Value: Not Disclosed

Exclusive financial advisor to Sun Healthcare and its subsidiary SolAmor Hospice on its acquisition of Countryside Hospice

Acadia Pharmaceuticals

Announced: 1/1/2011 | Value: $15 million

Co-placement agent for Acadia Pharmaceuticals Inc. in connection with raising $15 million in a PIPE financing

Aastrom Biosciences

Announced: 12/10/2010 | Value: $22.5 million

Financial advisor to Aastrom Biosciences for its $22.5 million follow-on offering

Neurologix

Announced: 12/6/2010 | Value: $7 million

Lead placement agent for Neurologix, Inc. in connection with raising $7 million in convertible debt

Reata Pharmaceuticals

Announced: 9/23/2010 | Value: $450 million

Strategic advisor to Reata Pharmaceuticals in its landmark ex-US partnership with Abbott Labs

Sun Healthcare

Announced: 8/13/2010 | Value: $238 million

Financial advisor to Sun Healthcare on its equity offering in connection with its restructuring and spinof of its real estate assets

Solstice Neurosciences

Announced: 8/13/2010 | Value: Not Disclosed

Exclusive financial advisor to Solstice Neurosciences, LLC on its sale to US WorldMeds

Trubion Pharmaceuticals

Announced: 8/12/2010 | Value: Up to $140 million

Financial advisor to Trubion Pharmaceuticals on its sale to Emergent Biosolutions

NuPathe

Announced: 8/6/2010 | Value: $50 million

Financial advisor to NuPathe, Inc in connection with its Initial Public Offering

Westcliff Medical Laboratories

Announced: 7/18/2010 | Value: $74 million

Exclusive financial advisor to Westcliff Medical Laboratories on its restructuring and sale to Laboratory Corporation of America

Accolade

Announced: 7/1/2010 | Value: $17 million

Sole placement agent for Accolade LLC on its $17 million Private Placement

Sun Healthcare

Announced: 5/24/2010 | Value: $1.6 billion

Financial advisor to Sun Healthcare on its spin of real estate assets into separately traded Sabra Health Care REIT (SBRA)

Inhibitex

Announced: 10/26/2009 | Value: $23 million

Exclusive placement agent for Inhibitex, Inc. in connection with raising $23 million in a PIPE financing

Threshold Pharmaceuticals

Announced: 10/6/2009 | Value: $35 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $35 million in a PIPE financing

Neurogen Corporation

Announced: 8/24/2009 | Value: $11 - 27 million

Exclusive financial advisor to Neurogen Corporation on its Sale to Ligand Pharmaceuticals Incorporated

Reata Pharmaceuticals

Announced: 3/27/2009 | Value: $32 million

Sole placement agent for Reata Pharmaceuticals, Inc on its $32 million Private Placement

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2009 | Value: $37 million

Divestiture of dental insurance business of a not-for-profit insurer

GTC Biotherapeutics

Announced: 11/3/2008 | Value: $15 million

Financial advisor to GTC Biotherapeutics, Inc on its $15 million Convertible Debt financing

Oscient Pharmaceuticals

Announced: 10/21/2008 | Value: $213 million

Dealer manager in connection with debt restructuring and recapitalization

Link Medicine

Announced: 9/30/2008 | Value: $40 million

Sole placement agent for Link Medicine Corporation on its $40 million Private Placement

Threshold Pharmaceuticals

Announced: 7/10/2008 | Value: $18 million

Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $18 million in a PIPE financing

My Innerview

Announced: 2008 | Value: Not Disclosed

Exclusive financial advisor in connection with its sale to National Research Corporation (NRCI)

Coram

Announced: 10/12/2007 | Value: $350 million

Exclusive financial advisor in connection with its sale to Apria (AHG)

Universal American (UAM)

Announced: 2007 | Value: $630 million

Financial advisor to priviate equity consortium in connection with its investment to fund the acquisition of MemberHealth

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2007 | Value: $125 million

Acquisition of CompWest

Coram

Announced: 2007 | Value: Not Disclosed

Sale of Canadian infusion portfolio

Sun Healthcare Group

Announced: 12/1/2006 | Value: $19 million

Exclusive financial advisor to Sun Healthcare on its sale of SunPlus Home Health Services to AccentCare Home Health

Sun Healthcare Group

Announced: 10/19/2006 | Value: $625 million

Exclusive financial advisor to Sun Healthcare on its acquisition of Harborside Healthcare

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2006 | Value: $240 million

Acquisition of M-Care

Coram

Announced: 2006 | Value: Not Disclosed

Sale of home infusion portfolio

Pacificare (PHSY)

Announced: 2005 | Value: $9 billion

Sale to UnitedHealthcare (UHG)

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2005 | Value: Not Disclosed

Sale of PPO Business

Sun Healthcare Group

Announced: 5/19/2005 | Value: $246 million

Financial advisor to Sun Healthcare on its acquisition of Peak Medical

Pacificare (PHSY)

Announced: 2005 | Value: Not Disclosed

Acquisition of Pacific Life’s group health insurance business

PresGar Companies

Announced: 2004 | Value: $135 million

Restructuring

PresGar Companies

Announced: 2004 | Value: Not Disclosed

Sale of imaging center portfolio to undislosed buyer

Pacificare (PHSY)

Announced: 2004 | Value: $532 million

Acquisition of American Medical Security Group (AMZ)

Sloans Lake

Announced: 2004 | Value: $45 million

Sale to undiclosed financial buyer

Sun Healthcare Group

Announced: 2/1/2004 | Value: $1.4 billion

Exclusive financial advisor to Sun Healthcare Group on its restructuring

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2004 | Value: $200 million

Structured Financing

Undisclosed Not-for-Profit Managed Care Organization

Announced: 2003 | Value: $150 million

Divestiture

Sun Healthcare Group

Announced: 9/1/2003 | Value: $75 million

Financial advisor to Sun Healthcare on its Senior Debt Financing

Sun Healthcare Group

Announced: 6/17/2003 | Value: $90 million

Exclusive financial advisor to Sun Healthcare on its sale of SunScript Pharmacy Services to Omnicare

Pacificare (PHSY)

Announced: 2002 | Value: $200 million

Advisor to PacifiCare in connection with its High-Yield Financing

The Mentor Network

Announced: 2001 | Value: $126 million

Sale to Madison Dearborn Capital Partners

Magellan Health Services (MGLN)

Announced: 2001 | Value: $250 million

Debt Financing

Schein Pharmaceuticals (SHP)

Announced: 2000 | Value: $1.4 billion

Sale to Watson Pharmaceuticals (WPI)